Recombinant human collagen (Shanxi Jinbo Biomedical)(Recombinant human collagen (Shanxi Jinbo Biomedical)) - 药物靶点：Collagen_在研适应症：糖尿病足溃疡_专利_临床

概要

基本信息

药物类型

重组蛋白

别名-

靶点

Collagen

作用机制

胶原蛋白调节剂

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [1]

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

3

项与 Recombinant human collagen (Shanxi Jinbo Biomedical) 相关的临床试验

ChiCTR2300069248 / Recruiting临床1期IIT

A clinical study to evaluate the effectiveness and safety of recombinant human collagen hydrogel applied to diabetic foot ulcer

开始日期2023-03-10

申办/合作机构-

ChiCTR2000037910 / Suspended早期临床1期IIT

Development of standardized clinical trial for in-situ regeneration of intelligent biomaterials and establishment of follow-up evaluation system

开始日期2020-09-01

申办/合作机构-

ChiCTR-IPR-15007266 / Completed临床1期IIT

The Safety And Efficacy Evaluation Of Recombinant Human Collagen Vaginal Gel For The Treatment Of Vaginal Dryness

开始日期2014-02-13

申办/合作机构

重庆医科大学附属第二医院

100 项与 Recombinant human collagen (Shanxi Jinbo Biomedical) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant human collagen (Shanxi Jinbo Biomedical) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant human collagen (Shanxi Jinbo Biomedical) 相关的专利（医药）

登录后查看更多信息

1,095

项与 Recombinant human collagen (Shanxi Jinbo Biomedical) 相关的文献（医药）

2024-06-01·Reproductive BioMedicine Online

Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35–40 years

Article

作者: Fischer, Robert ; Schwarze, Juan-Enrique ; Chuderland, Dana ; D'Hooghe, Thomas ; Bielfeld, Alexandra P ; Lispi, Monica ; Hayward, Brooke ; Verpillat, Patrice ; Krussel, Jan-Steffan

RESEARCH QUESTIONAccording to real-world data, is recombinant human FSH (r-hFSH) combined with recombinant human LH (r-hLH) or r-hFSH alone more effective for women of advanced maternal age (AMA) in terms of live birth?DESIGNNon-interventional study comparing the effectiveness of r-hFSH and recombinant r-hLH (2:1 ratio) versus r-hFSH alone for ovarian stimulation during ART treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register.RESULTSOverall clinical pregnancy (29.8%, 95% CI 28.2 to 31.6 versus 27.8%, 95% CI 26.5 to 29.2) and live birth (20.3%, 95% CI 18.7 to 21.8 versus 18.0%, 95% CI 16.6 to 19.4) rates were not significantly different between the combined r-hFSH and r-hLH group and the r-hFSH alone group (P = 0.269 and P = 0.092, respectively). Treatment effect was significantly higher for combined r-hFSH and r-hLH compared with r-hFSH alone for clinical pregnancy (33.1%, 95% CI 31.0 to 35.0 versus 28.5%, 95% CI 26.6 to 30.4; P = 0.001, not adjusted for multiplicity) and live birth (22.5%, 95% CI 20.5 to 24.2 versus 19.4%, 95% CI 17.6 to 20.9; P = 0.014, not adjusted for multiplicity) in a post-hoc analysis of women with five to 14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of combined r-hFSH and r-hLH for ovarian stimulation in women aged 35-40 years with normal ovarian reserve.CONCLUSIONSWomen of AMA with normal ovarian response benefit from treatment with combined r-hFSH and r-hLH in a 2:1 ratio versus r-hFSH alone in terms of live birth rate. The effectiveness of treatments is best assessed by RCTs; however, real-world data are valuable for examining the effectiveness of fertility treatment, especially among patient groups that are not well represented in clinical trials.

2024-03-29·Endocrinology

Adiponectin Inhibits the Progression of Obesity-Associated Papillary Thyroid Carcinoma Through Autophagy

Article

作者: Dionigi, Gianlorenzo ; Liang, Nan ; Sun, Hui ; Guan, Haixia ; Zhang, Jiao ; Li, Changlin

AbstractContextObesity is a risk factor for the development of papillary thyroid cancer (PTC). However, the molecular mechanisms by which obesity promotes PTC are unclear.ObjectiveThis study aims to identify adipokines that are linked to PTC progression.MethodsAn adipokine antibody array was used to determine the serum levels of 40 adipokines in normal-weight and obese PTC patients. Enzyme-linked immunosorbent assay was used to determine the serum levels of adiponectin. Recombinant human adiponectin was produced by human adipose-derived stem cells and used to treat PTC cells. Cell proliferation and migration were evaluated using the CCK8 and Transwell assays. Bioinformatics analysis was used to predict mechanisms by which adiponectin affects PTC.ResultsAdipokines differentially expressed between normal-weight and obese patients showed a gender-dependent pattern. Obese PTC patients had a significantly lower serum adiponectin level than normal-weight patients, especially in female individuals. Adiponectin levels were negatively correlated with aggressive features of PTC, including tumor diameter > 1 cm, extrathyroidal extension, and lymph node metastasis. Recombinant human adiponectin inhibited the proliferation and migration of human PTC cells in vitro. Bioinformatics analysis identified adiponectin receptor 2 (ADIPOR2) and the autophagy pathway as possible mediators of adiponectin function in TC. In vitro experiments confirmed that adiponectin activated autophagy in PTC cells. These findings shed new lights into the role and mechanisms of adiponectin in TC pathogenesis.ConclusionAdiponectin is involved in development of obesity-related PTC. Adiponectin can directly inhibit thyroid cancer growth and metastasis through the autophagy pathway.

2024-03-01·The Journal of Thoracic and Cardiovascular Surgery

Mitsugumin 53 mitigation of ischemia–reperfusion injury in a mouse model

Article

作者: Lee, Yong Gyu ; Zhu, Hua ; Whitson, Bryan A ; Ma, Jianjie ; Zhang, Zhentao ; Gouchoe, Doug A ; Kim, Jung Lye ; Ganapathi, Asvin ; Marshall, Joanna M ; Black, Sylvester M

OBJECTIVEPrimary graft dysfunction is often attributed to ischemia-reperfusion injury, and prevention would be a therapeutic approach to mitigate injury. Mitsugumin 53, a myokine, is a component of the endogenous cell membrane repair machinery. Previously, exogenous administration of recombinant human (recombinant human mitsugumin 53) protein has been shown to mitigate acute lung injury. In this study, we aimed to quantify a therapeutic benefit of recombinant human mitsugumin 53 to mitigate a transplant-relevant model of ischemia-reperfusion injury.METHODSC57BL/6J mice were subjected to 1 hour of ischemia (via left lung hilar clamp), followed by 24 hours of reperfusion. mg53^-/- mice were administered exogenous recombinant human mitsugumin 53 or saline before reperfusion. Tissue, bronchoalveolar lavage, and blood samples were collected at death and used to quantify the extent of lung injury via histology and biochemical assays.RESULTSAdministration of recombinant human mitsugumin 53 showed a significant decrease in an established biometric profile of lung injury as measured by lactate dehydrogenase and endothelin-1 in the bronchoalveolar lavage and plasma. Biochemical markers of apoptosis and pyroptosis (interleukin-1β and tumor necrosis factor-α) were also significantly mitigated, overall demonstrating recombinant human mitsugumin 53's ability to decrease the inflammatory response of ischemia-reperfusion injury. Exogenous recombinant human mitsugumin 53 administration showed a trend toward decreasing overall cellular infiltrate and neutrophil response. Fluorescent colocalization imaging revealed recombinant human mitsugumin 53 was effectively delivered to the endothelium.CONCLUSIONSThese data demonstrate that recombinant human mitsugumin 53 has the potential to prevent or reverse ischemia-reperfusion injury-mediated lung damage. Although additional studies are needed in wild-type mice to demonstrate efficacy, this work serves as proof-of-concept to indicate the potential therapeutic benefit of mitsugumin 53 administration to mitigate ischemia-reperfusion injury.

100 项与 Recombinant human collagen (Shanxi Jinbo Biomedical) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病足溃疡	临床1期	中国	山西锦波生物医药股份有限公司	2023-03-10
阴道粘膜干燥	药物发现	中国	山西锦波生物医药股份有限公司	2014-02-13